

Curriculum Vitae

DATE: July 15, 2011
NAME: Jonathan Foulds, PHD
PRESENT TITLE: Professor of Public Health Sciences & Psychiatry
Pennsylvania State University, College of Medicine

ADDRESS: (office) Cancer Institute H069, 500 University Drive, PO Box 850
Hershey, PA 17033, USA
Email: jfoulds@psu.edu phone: 717 531 3504
Personal Email: jonathanfoulds@hotmail.com

CITIZENSHIP: British (USA Permanent Resident)

UNDERGRADUATE EDUCATION:

8/1982 – 6/83 Andrew College, Georgia, USA
Year of study financed by a Soccer Scholarship.
Majored in Psychology. (Grade Point Average = 4.0)

9/83 – 6/87 University of Aberdeen, Scotland
Degree: Master of Arts (M.A.) in Psychology, with First Class Honors
Thesis title: "Level of Socialization and its relationship to Electrodermal Activity and Behavioral Inhibition"

GRADUATE EDUCATION:

9/87 – 8/89 University of Glasgow, Scotland
Degree: Master of Applied Science (M.App.Sci.) in Clinical Psychology
Thesis title: "Blood-injury Phobia: Psychophysiology and Treatment"

1/90 – 7/97 University of London, Institute of Psychiatry (part-time)
Degree: Doctor of Philosophy (Ph.D.) in Psychology (1997)
Thesis Title: "An Investigation Into The Role of Nicotine in Tobacco Smoking and Smoking Cessation"

POST GRADUATE TRAINING:

9/89 – 8/90 One year clinical psychology internship. Maudsley Hospital, Camberwell, London.

ACADEMIC APPOINTMENTS:

- 9/89 - 7/94 Research Clinical Psychologist, Institute of Psychiatry, Health Behaviour Unit, 4 Windsor Walk, Camberwell, London SE5
- 8/94 – 8/97 Lecturer in Addictive Behaviour, Department of Addictive Behaviour, St George's Hospital Medical School, University of London, London SW17
- 9/97 – 8/2000 Senior Lecturer in Clinical Psychology, Department of Psychology, University of Surrey, Guildford, Surrey GU2 5XH
- 3/2000 – 8/00 Director of Research, Quit (U.K. smoking cessation charity)
- 9/2000 – 6/2007 Associate Professor, University of Medicine and Dentistry of New Jersey – School of Public Health
- 9/2000 – 6/2010 Director, Tobacco Dependence Program, UMDNJ-School of Public Health
- 7/2007 – 6/2010 Professor, University of Medicine and Dentistry of New Jersey – School of Public Health
- 5/2009 – 6/2010 Full Member, Public Health graduate faculty, Rutgers University, New Jersey
- 8/2010- continuing Professor of Public Health Sciences, Penn State University, College of Medicine

HOSPITAL APPOINTMENTS:

- 10/89 – 7/94 Honorary Clinical Psychologist, Maudsley Hospital, London
- 9/91 – 4/99 Clinical Psychologist in Primary Care: Kingston and District Community NHS Trust
- 1/96 – 8/97 Coordinator: St George's Hospital Smoking Cessation Service
- 2/98 – 8/2000 Principal Clinical Psychologist, Broadmoor Hospital

OTHER EMPLOYMENT:

Consultancy work carried out for: Health Education Authority (UK), Medicine's Control Agency (UK), Department of Health (UK), South Yorkshire Police Force, Cline, Davis & Mann Marketing, Free and Clear Inc., New York State Comprehensive Tobacco Control Program, Pfizer Inc., Knoll Pharmaceuticals Inc., Pharmacia & Upjohn (now Pfizer), Novartis, Glaxo Smithkline, Cypress Bioscience and Celtic Pharma pharmaceutical companies. On the Pfizer Chantix Speakers Bureau 2006-2008. Wrote a regular column on "Freedom From Smoking" for a health website at: www.healthline.com/blogs/smoking_cessation/ (2006-10). Health Expert on www.WebMD.com 2010- Serve as reviewer on Pfizer "GRAND" research grant program, and on Pfizer, Novartis, Cypress Bioscience and GSK's Smoking Cessation Advisory Committees.

Have acted as an expert witness for the Crown Prosecution Service (UK) in a case focusing on mental impairment caused by nicotine withdrawal, and as an expert witness for plaintiffs in litigation against tobacco companies (submitted reports and deposed but not required to testify in court):

Short vs Reynolds (smoking caused death)
Gaston vs Reynolds and Philip Morris (smoking caused death)
Mueller vs Philip Morris, Ligget (smoking caused illness case)

The plaintiff's law firm was Robert Jaffe & Associates of Springfield NJ.
Gesser v Philip Morris (Lights case) (Trujillo, Rodriguez & Richards, LLC)
Hess v Philip Morris etc
Stephens v Reynolds etc
Sherman v Reynolds etc
Cohen v Reynolds etc (Paige, Trop and Ameen PA, in Florida, Engle-related cases)

LICENSURE:

Chartered Clinical Psychologist, and Chartered Health Psychologist (on the Register of Chartered Psychologists of the British Psychological Society 1990-2008).

CERTIFICATION:

Certified Tobacco Treatment Specialist (The Certification Board Inc.), since 2004.

PROFESSIONAL ORGANIZATIONS AND COMMITTEES:

British Psychological Society (membership number: 23187) 1987 to 2008.
Society for Research on Nicotine and Tobacco, 2000, continuing (serve on the SRNT website committee).
Association for the Treatment of Tobacco Use and Dependence (serve on the Training and Policy Committees).

HONORS, AWARDS, OTHER POSITIONS:

1995 – 1997	Management Group Member, Population-Based Anti-Smoking Program, Hungary.
1999 - 2001	Technical Leader on World Health Organization European Partnership Project To Reduce Tobacco Dependence, Activity Area: Regulation of Treatment Products.
2000 – Present	Member of New Jersey Commissioner’s Advisory Committee on Tobacco Dependence Treatment.
2001 – Present	Member, Cancer Institute of New Jersey
2002 - Present	Board member, New Jersey Institute for Continuing Education in Tobacco.
2002 – 2006	Science-based Initiatives Chair, NJ Institute for Continuing Education in Tobacco.
2003 – 2006	Board member, Vice President and Communications Committee Chair: Association for the Treatment of Tobacco Use and Dependence.
2003 - Present	Website Committee Member: Society for Research on Nicotine and Tobacco.
2007- Present	International Committee member, Association for the Treatment of Tobacco Use and Dependence.
2007	Recipient of UMDNJ-SPH “Community-Campus Partnership Award”.
2008-Present	Chantix National Advisory Board member (Pfizer)

2008	National Committee for Quality Assurance, Focus on Smoking Cessation Advisory Board.
2008	Member, National Committee on Quality Assurance, Smoking Cessation Measurement Workgroup.
2008- Present	Novartis International Smoking Cessation Advisory Board.
2008- Present	Member, Editorial Board and Efficacy Section, www.treatobacco.net
2009	New Jersey GASP award in recognition of smoking cessation expertise.
2010	Consultant. American Dental Association, Guideline of Smoking Cessation Products
2010	Member, Penn State Hershey Cancer Institute (PSHCI)

EDITORIAL POSITIONS:

Member of the Editorial Board: International Journal of Clinical Practice

Referee for the following Journals:

JAMA, British Medical Journal, Lancet, Lancet (Neurology), Cancer Epidemiology Biomarkers & Prevention, Addiction, Psychopharmacology, Preventive Medicine, Drug And Alcohol Dependence, Addiction Research, Health Education Research, Nicotine and Tobacco Research, Tobacco Control, Drugs and Therapeutics Bulletin, and others. Also review submissions to national conferences, e.g. National Conference on Tobacco or Health, 2003 and 2005, SRNT annual conference 2006 & 2007.

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

Refereed grant applications for: Medical Research Council (UK), the National Health Service Research & Development Programme (UK), Department of Health (UK), the Pfizer GRAND program, the Nuffield Foundation, and US National Institutes of Health (NIMH/NIDA/NCI/NIAAA).

SERVICE ON GRADUATE SCHOOL COMMITTEES:

(when at UMDNJ) Elected member of the UMDNJ School of Public Health By-Laws Committee.

Member of the UMDNJ SPH Executive Council.

Member of the UMDNJ SPH Doctoral Committee

Served on the ad-hoc UMDNJ SPH "Tobacco Industry Funding sub-committee"

SPONSORSHIP OF CANDIDATES FOR POSTGRADUATE DEGREE:

In the United Kingdom supervised numerous MSc (Addictive Behavior) graduate students at St George's Hospital Medical School, and numerous MS and PsyD graduate students at University of Surrey.

Regularly supervise MPH fieldwork research projects for MPH students.

Also supervised PhD/DrPH projects (most recently Tyree Oredein) and was the primary mentor on two NIH, K-Awards (Dr Marc Steinberg and Dr Ed Budreaux: Department of Psychiatry at UMDNJ-RWJFMS)

TEACHING RESPONSIBILITIES:

Previously (at UMDNJ) taught on the 5-day training for Tobacco Dependence Treatment Specialists and various other trainings organized by the Tobacco Dependence Program as well as supervision of MPH student projects. Contribute to the MPH in Public Health curriculum, MD curriculum, and DMD

curriculum as required. Teach on tobacco addiction to psychiatry residents, some of whom do a clinical placement.

GRANT SUPPORT:

1. World Bank/Hungarian Ministry of Welfare. Population-Based National Anti-Smoking Campaign. 1995-1997. \$ 1,000,000. \$100,000 to St George's Group: J Foulds (PI) on UK component and a member of the Management Group for this Hungarian national campaign.
2. Health Education Authority. Factors Affecting the Uptake of Smoking in Young People. 1995-1997. £45,000 to J Foulds (PI).
3. Pharmacia & Upjohn. Comparison of Nicotine Replacement Products For Smoking Cessation: A Randomized Trial. 1995-1997. £140,000 to P Hajek (PI), R West, J Foulds et al.
4. Health Education Authority. Evaluation of Smoke-Free Schools Guidelines in Merton, Sutton and Wandsworth. 1997. £10,000 to J Foulds (PI).
5. West Surrey Health Authority. Survey of smoking cessation practice in health professionals in West Surrey. 1999 £6,000 to J Foulds (PI).
6. Centers For Disease Control & Prevention (CDC). Pilot Evaluation of Internet Smoking Cessation. 2001-3. \$120,000 to J Foulds (PI).
7. UMDNJ-SPH Curriculum Innovations Grant. Integrating Tobacco into a Public Health Curriculum. 2002. \$8,500 to M Burke (PI), J Foulds et al.
8. New Jersey Department of Health & Senior Services, Division of Addiction Services. Tobacco Dependence Program 2002-3. \$1,504,910 to J Foulds (PI).
9. Association of Schools of Public Health/ American legacy. Comprehensive Tobacco Control: web-based Integration into the Public Health Curriculum. 2002-3. \$50,000 to M Burke (PI), J Foulds et al.
10. Association of Schools of Public Health/ American legacy. Comprehensive Tobacco Control: web-based Integration into the Public Health Curriculum. 2003-5. \$100,000 to M Burke (PI), J Foulds, et al.
11. New Jersey Department of Health & Senior Services, Division of Addiction Services. Smoking Cessation in New Jersey High Schools. 2003. \$75,000 to J Foulds (PI).
12. National Institute on Drug Abuse. Treatment of Nicotine Addiction in Schizophrenia. 2003-2006. \$1,513,905 to D Ziedonis (PI), J Foulds et al.
13. New Jersey Department of Health & Senior Services, Division of Addiction Services. Tobacco Dependence Program 2003-4. \$1,200,000 to J Foulds (PI).
14. New Jersey Department of Health & Senior Services, Tobacco Dependence Program 2004-5. \$825,000 to J Foulds (PI).

15. Associated Treatment Providers of New Jersey, Addressing Tobacco in the Treatment of Other Addictions 2004-5. \$80,000 to J Foulds (P.I.)
16. Cancer Institute of New Jersey, CINJ Mentored Research Award: Evaluating New Treatments or Tobacco Dependence 2004-6. \$200,000 to J Foulds (P.I.)
17. Robert Wood Johnson Foundation, New Jersey Health Initiative. Developing Culturally Competent Hispanic Smoking Cessation Outreach for New Jersey. 2005-7, \$273,000 to J Foulds (P.I.).
18. Associated Treatment Providers of New Jersey, Addressing Tobacco in the Treatment of Other Addictions 2005-6. \$97,000 to J Foulds (P.I.)
19. New Jersey Department of Health & Senior Services. Tobacco Dependence Program 2005-6. \$720,000 to J Foulds (PI).
20. National Institute on Drug Abuse. Strategies To Help ER Patients Quit Smoking. R-21 DAO17812-01A1. 2005-7. \$200,000 to S Bernstein (P.I.), J Foulds et al.
21. New Jersey Department of Health & Senior Services. Tobacco Dependence Program 2006-7. \$500,000 to J Foulds (PI).
22. New Jersey Department of Health & Senior Services. Youth Quit2Win: Youth Tobacco Cessation Program. 2006-7. \$100,000 to J Foulds (PI).
23. New Jersey Department of Health & Senior Services. Tobacco Dependence Clinic 2006-7. \$108,000 to J Foulds (PI).
24. New Jersey Department of Health & Senior Services. Middlesex Partnership Against Tobacco 2006-7. \$80,000 to J Foulds (PI).
25. Robert Wood Johnson Foundation. Proyecto Vida: Latino Deje De Fumar.. 2006-7, \$60,000 to J Foulds (PI).
26. Robert Wood Johnson Foundation (to SRNT). Barriers to consumer demand for FDA-approved tobacco treatment medications: implications for policy action. 2006-7. \$30,000 to J Foulds (PI).
27. New Jersey Department of Health & Senior Services. Tobacco Dependence Program 2007-8. \$788,000 to J Foulds (PI).
28. New Jersey Department of Health & Senior Services. Tobacco Dependence Program 2008-9. \$588,000 to J Foulds (PI).
29. Florida State University. Florida AHEC Tobacco Training and Cessation. 2008. \$123,390 to J Foulds (PI).
30. American Lung Association (Washington DC). Tobacco dependence treatment training. 2008-9 \$99,000. To J Foulds (P.I.), M Steinberg.

30. Rutgers Community Health Foundation. Smoking cessation outreach to communities of color in New Brunswick. 2008-2010. \$169,000 to J Foulds (PI).
31. New Jersey Department of Health & Senior Services. Tobacco Dependence Program 2009-10. \$558,000 to J Foulds (PI).
32. Wellpoint Inc. Development and training for a new quitline curriculum. 2009-10. \$40,608 to J Foulds (PI) and M Steinberg.

PUBLICATIONS:

Articles in Peer-reviewed Journals

1. Foulds J, McAllister H, Foulds S. The relationship between socialization and electrodermal activity in normal subjects. *J Psychophysiol* 1988; 2: 227-230.
2. Crawford JR, Stuart LE., Cochrane RHB, Foulds J, Besson JAO, Parker DM. Predicting premorbid IQ from demographic variables: a regression equation derived from a UK sample. *Brit J Clin Psychol* 1989; 28: 275-278.
3. Foulds J, Weidmann K, Patterson L, Brooks N. The effects of muscle tension on cerebral circulation in blood-phobic and non-phobic subjects. *Behav Res Ther* 1990; 28: 481-486.
4. Foulds J, Stapleton J, Feyerabend C., Vesey C, Jarvis M., Russell MAH. Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study. *Psychopharmacology* 1992; 106: 421-427.
5. Jarvis M, Foulds J, Feyerabend C. Exposure to passive smoking among bar staff. *Brit J Addiction* 1992; 87: 111-113.
6. Foulds J. Cerebral circulation during treatment of blood-injury phobia: a case study. *Behav Psychotherapy* 1993; 21: 37-146.
7. Foulds J. Does nicotine replacement therapy work? *Addiction* 1993; 88: 1473-1478.
8. Foulds J, Stapleton J, Hayward M., Russell MAH, Feyerabend C., Fleming T, Costello J. Transdermal nicotine patches with low- intensity support to aid smoking cessation in outpatients in a general hospital: a placebo-controlled trial. *Arch Fam Med* 1993; 2: 417-423.
9. Foulds J. Nicotine replacement does work: time to stop sitting on the fence. *Addiction* 1994; 89: 438-439.
10. Foulds J. Detrimental effects of nicotine on mood? *Addiction* 1994; 89: 136-138.
11. Foulds J, Ghodse H. Treatment of tobacco dependence. *Advances in Psychiatric Treatment* 1995; 1: 116-123.
12. Foulds J, McSorley K, Sneddon J, Feyerabend C., Jarvis MJ, Russell MAH. Effect of subcutaneous nicotine injections on EEG alpha frequency in non-smokers: a placebo-controlled pilot study. *Psychopharmacology* 1994; 115: 163-166.
13. Foulds J, Bryant A, Stapleton J, Jarvis M, Russell MAH. Stability of cotinine in unfrozen saliva mailed to the laboratory. *Am J Pub Health* 1994; 84: 1182-1183. (let)

14. Foulds J, Toone B A case of nicotine psychosis? *Addiction* 1995; 90: 435-437
15. Foulds J, Feyerabend C, Stapleton J, Jarvis MJ, Russell MAH. Stability of nicotine and cotinine in unfrozen plasma. *J Smoking-Related Disorders* 1994; 5: 41-44
16. Foulds J, Stapleton J. Evidence that cotinine is psychoactive? *Clin Pharmacol Ther* 1995; 57: 95. (let)
17. Foulds J, Godfrey C. Counting the cost of children's smoking. *BMJ* 1995; 311: 1152-4
18. Foulds J, Ghodse A.H. The role of nicotine in tobacco smoking: implications for tobacco control policy. *J Royal Soc Health* 1995; 115: 225-230.
19. Foulds J. Never too late to stop smoking. *Geriatric Medicine* 1996; 26: 13
20. Foulds J. Strategies for smoking cessation. *Brit Med Bull* 1996; 52: 157-173.
21. Foulds J. A role for dopamine in nicotine psychosis? *Addiction* 1996; 91: 1388-89 (let)
22. Foulds J, Stapleton J, Swettenham J, Bell N, McSorley K, Russell MAH. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. *Psychopharmacology* 1996; 127: 31-38.
23. Foulds J, Stapleton J, Bell N, Swettenham J, Jarvis MJ, Russell MAH. Mood and physiological effects of subcutaneous nicotine in smokers and never-smokers. *Drug Alc Dep* 1997; 44: 105-115.
24. Foulds J, Russell MA, Jarvis MJ, Feyerabend C. Nicotine absorption and dependence in unlicensed lozenges available over the counter. *Addiction* 1998; 93: 1427-31.
25. Foulds J. The relationship between tobacco use and mental disorders. *Curr Op Psychiatry* 1999; 12: 303-306.
26. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomised comparative trial of nicotine polacrilex, transdermal patch, nasal spray and inhaler. *Arch Int Med* 1999; 159: 2033-2038.
27. Foulds J. Killing for profit: where is the outrage? *BMJ* 1999; 319: 266
28. Foulds J. The psychology of tobacco addiction: why it is difficult to stop smoking. *Monaldi Arch Chest Dis* 1999; 54: 495-497.
29. West R, Hajek P, Foulds J, Nilsson F, Burrows S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. *Psychopharmacology* 2000; 149: 198-202.
30. Foulds J. The new NHS smoking campaign. *BMJ* 2000; 320: 454
31. West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A. Individual differences in preferences for and responses to four nicotine replacement products. *Psychopharmacology* 2001; 153: 225-230

32. Hajek P, West R, Lee A, Foulds J, Eiser JR, Main N. Randomized controlled trial of a midwife-delivered brief smoking cessation intervention in pregnancy. *Addiction* 2001; 96: 485-494.
33. Herbert M, Foulds J, Fife-Schaw C. No effect of cigarette smoking on attention or mood in non-deprived smokers. *Addiction* 2001; 96: 1349-1356.
33. McNeill A, Foulds J, Bates C. Regulation of nicotine replacement therapies (NRT): a critique of current practice. *Addiction* 2001; 96: 1757-1768.
34. Foulds J, Burke M, Richardson D & Kazimir E. Tobacco dependence treatment services in New Jersey. *New Jersey Medicine* 2002; 99: 23-28
35. Foulds J. Smoking cessation services show good return on investment. *BMJ* 2002; 324: 608-609 (let).
36. Harakas P, Foulds J. Acute effects of glucose tablets on craving, withdrawal symptoms, and sustained attention in 12-h abstinent tobacco smokers. *Psychopharmacology* 2002; 161:271-277.
37. Krejci J, Foulds J. Engaging patients in tobacco dependence treatment: assessment and motivational techniques. *Psychiatric Annals* 2003; 33:436-444.
38. May S, West R, Hajek P, Nilsson F, Foulds J, Meadow A. The use of videos to inform smokers about different nicotine replacement products. *Patient Education and Counselling* 2003; 51:143-7
39. Foulds J, Ramstrom L, Burke M, Fagerstrom K. The effect of smokeless tobacco (snus) on public health in Sweden. *Tobacco Control* 2003; 12:349-59.
40. Foulds J, Burke M, Steinberg M, Williams J, Ziedonis D. Advances in pharmacotherapy for tobacco dependence. *Expert Opinion in Emerging Drugs* 2004; 9:39-53.
41. Steinberg M, Delnevo C, Foulds J, Pevzner E. Characteristics of smoking and cessation among high school students in New Jersey. *Journal of Adolescent Health* 2004; 35: 231-133.
42. Williams J, Ziedonis DM, Foulds J. Nicotine nasal spray in the combination treatment of tobacco dependence in schizophrenia: a case series. *Psychiatric Services* 2004; 55: 1064-1066.
43. Delnevo C, Hrywna M, Foulds J, Steinberg MB. Cigar use after a cigarette excise tax increase in New Jersey. *Addictive Behaviors* 2004; 29:1799-1807
44. Foulds J, Williams J. Tobacco use, cataracts and schizophrenia. *American Journal of Psychiatry* 2005; 161:1113-1115 (let)
45. Williams J, Foulds J, Dwyer M, Order-Conners B, Springer M, Gadde P, Ziedonis DM. The integration of tobacco dependence treatment and tobacco-free standards into residential addictions treatment in New Jersey. *Journal of Substance Abuse Treatment* 2005; 28: 331-42.
46. Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and

- schizoaffective disorder is not a metabolic effect. *Schizophr Res.* 2005; 79:323-335.
47. Delnevo CD, Foulds J, Hrywna M. Trading tobacco: are youth choosing cigars over cigarettes? *Am J Public Health* 2005; 95: 2123
 48. Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Pharmacotherapy for tobacco dependence: past , present and future. *Drug and Alcohol Review* Jan 2006; 25:57-69
 49. Foulds J, Ramstrom R. Causal effects of smokeless tobacco on mortality in CPS-I and CPS-II? *Cancer Causes and Control.* 2006 17 (2): 227-228 (let).
 50. Delnevo CD, Foulds J, Vorbach U, Kazimir E. Seasonal variations in stage of change among Quitline clients. *Tobacco Control.* 2006; 15: 70-71 (let).
 51. Steinberg MB, Foulds J, Richardson DL, Burke MV, Shah P. Pharmacotherapy and smoking cessation at a tobacco dependence clinic. *Preventive Medicine* 2006; 42:114-119.
 52. Ziedonis DM , Williams JM, Steinberg ML, Foulds J. Addressing tobacco addiction in office-based management of psychiatric disorders: practical considerations. *Primary Psychiatry* 2006;13: 51-63
 53. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. *International Journal of Clinical Practice.* 2006; 60 (5) 571-576.
 54. Foulds J, Williams JM, Gandhi KK. Racial differences in lung cancer. *New England Journal of Medicine* 2006; 354; 18: 1952 (let.)
 55. Foulds J, Gandhi KK, Steinberg MB, Richardson D, Williams J, Burke M, Rhoads GG. Factors associated with quitting smoking at a tobacco dependence treatment clinic. *American Journal of Health Behavior* 2006; 30:400-412
 56. Ramström LM, Foulds J. The role of snus (smokeless tobacco) in initiation and cessation of tobacco smoking in Sweden. *Tobacco Control* 2006 Jun;15(3):210-4.
 57. Ziedonis D, Haberstroh S, Zimmermann MH, Miceli M, Foulds J. Adolescent tobacco use and dependence: assessment and treatment strategies. *Adolescent Medicine Clinics* 2006 June; 17(2): 381-410.
 58. Han ES, Foulds J, Steinberg MB, Gandhi KK, West B, Richardson D, Zelenetz S, Dasika J. Characteristics and smoking cessation outcomes of patients returning for repeat tobacco dependence treatment. *International Journal of Clinical Practice* 2006 September; 60(9): 1068-1074.
 59. Ziedonis DM, Guydish J, Williams J, Steinberg M, Foulds J. Barriers and solutions to addressing tobacco dependence in addiction treatment programs. *Alcohol Research and Health* 2006; 29(3): 228-235.
 60. Foulds J, Williams JM, Order-Connors B, Edwards N, Dwyer N, Kline A, Ziedonis DM. Integrating tobacco dependence treatment and tobacco-free standards into addiction treatment: the New Jersey experience. *Alcohol Research and Health* 2006; 29(3): 236-240

61. Williams J, Foulds J. Successful tobacco dependence treatment in schizophrenia. *American Journal of Psychiatry* 2007 February; 164(2):222-227
62. Delnevo C, Lewis MJ, Foulds J. Taxing moist snuff by weight ain't worth spit. *Tobacco Control* 2007 Feb;16(1):69.
63. Foulds J, Kozlowski LT. Snus: What should the public health response be? *Lancet* 2007 June 16; 369:1976-78
64. Williams JM, Gandhi KK, Steinberg ML, Foulds J, Ziedonis DM, Benowitz NL. Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia. *Nicotine Tob Res.* 2007 Aug;9(8):873-81.
65. Kozlowski LT, Giovino GA, Edwards B, DiFranza J, Foulds J, Hurt R, Niaura R, Sachs DPL, Selby P, Dollar KM., Bowen D, Cummings KM, Counts M, Fox B, Sweanor D, Ahern F. Advice on using over-the-counter nicotine replacement therapy- patch, gum, or lozenge- to quit smoking. *Addictive Behaviors.* 2007 Oct;32(10):2140-50.
66. Steinberg MB, Foulds J. Rimonabant for treating tobacco dependence. *Vasc Health Risk Manag.* 2007;3(3):307-11.
67. Bover MT, Foulds J, Steinberg MB, Richardson D, Marcella SW. Waking at night to smoke as a marker for tobacco dependence: Patient characteristics and relationship to treatment outcome. *International Journal of Clinical Practice.* Feb 2008; 62(2):182-190.
68. Steinberg MB, Schmelzer AC, Richardson D, Foulds J. Treating tobacco dependence as a chronic disease: a case illustration. *Annals of Internal Medicine* 2008 Apr 1;148(7):554-6.
69. Foulds J, Furberg H. Is low-nicotine Marlboro snus really snus? *Harm Reduction Journal.* 2008; 5 (9) 5-9.
70. Foulds J. Improving NRT labeling and correcting public misperceptions. *Addiction* 2008; 103: 1379-1380
71. Williams JM, Gandhi KK, Karavidas MK, Steinberg M, Lu SE, Foulds J. Open label study of craving in smokers with schizophrenia using nicotine nasal spray compared to nicotine patch. *Journal of Dual Diagnosis* 2008 4(4): 355-376
72. Gandhi KK, Foulds J, Steinberg MB, Lu SE, Williams J. Lower quit rates among menthol cigarette smokers at a tobacco treatment clinic. *International Journal of Clinical Practice* 2009 Mar;63(3):360-7.
73. Steinberg MB, Greenhaus S, Schmelzer AC, Bover M, Foulds J, Hoover DR, Carson JL. Randomized trial of triple combination extended duration pharmacotherapy versus standard duration nicotine patch alone for smokers with medical illness. *Annals of Internal Medicine* 2009 150(7): 447-454
74. Foulds J, Schmelzer AC, Steinberg MB. Treating tobacco dependence as a chronic illness and a key modifiable predictor of disease. *International Journal of Clinical Practice* 2010 Jan; 64(2): 142-146.

75. Foulds J. Use of nicotine replacement therapy to treat nicotine withdrawal syndrome and aid temporary abstinence. *International Journal of Clinical Practice* 2010 Feb; 64(3): 292-294.
76. Foulds J, Parth J, Bover-Manderski M. Blood glucose levels produced by glucose tablets in abstaining smokers. *Psychopharmacology* 2010; 209:283-284
77. Williams J, Gandhi KK, Lu SE, Kumar S, Shen J, Foulds J, Kipen H, Benowitz NL. Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. *Nicotine and Tobacco Research* 2010 Aug; 12(8): 855-9
78. Steinberg ML, Williams J, Gandhi KK, Foulds J, Brandon T. Lower task persistence in smokers with schizophrenia as compared to non-psychiatric control smokers. *Psychol Addict Behav.* 2010 Dec;24(4):724-9.
80. Foulds J, Pletcher M, Hooper M, Okuyemi K. Do smokers of menthol cigarettes find it harder to quit smoking? *Nicotine and Tobacco Research* 2010 Dec; 12(Supplement 2): S102-S109.
81. Steinberg MB, Boveri MT, Richardson DL, Schmelzer AC, Williams JM, Foulds J. Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies. *Drug and Alcohol Dependence* 2011; 114: 77-81
82. Borland R, Fagerstrom K, Foulds J, McNeill A, Ramstrom L. FCTC background report on smokeless tobacco is incompatible with WHO scientific reports. *Addiction* 2011 Jan;106(1):225-7. doi: 10.1111/j.1360-0443.2010.03250.x.
83. Williams JM, Steinberg M, Steinberg ML, Gandhi KK, Foulds J. Review of varenicline for tobacco dependence: panacea or plight? *Expert Opin Pharmacother.* 2011 Aug;12(11):1799-812.
84. Williams JM, Zimmermann MH, Steinberg ML, Gandhi KK, Delnevo C, Steinberg MB, Foulds J. A Comprehensive Model for Mental Health Tobacco Recovery in New Jersey. *Administration and Policy in Mental Health and Mental Health Services Research* (in press). doi: 10.1007/s10488-010-0324-x
85. Oredein T & Foulds J. What caused the decline in cigarette smoking among African-American youth from the 1970s to the 1990s? *Am J Public Health* (in press).
86. Foulds J, Veldheer S & Berg A. Electronic cigarettes: views of aficionados and clinical/public health perspective. *Int J Clinical Practice* (in press).
87. Foulds J, Veldheer S. Could E-cigs become the ultimate nicotine maintenance device? Commentary on Etter and Bullen: Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. *Addiction.* (in press).

Invited Book Chapters:

1. Foulds, J. and Jarvis, M.J. Smoking cessation and prevention. In Calverley, P. and Pride, N. (Eds) *Chronic Obstructive Pulmonary Diseases*, Chapman & Hall, London 1995, pp373-390.
2. Foulds, J. Nicotine replacement therapy: availability, abuse liability and dependence potential. In Tudor-Smith, C. (Ed) *Tackling Tobacco*. Health Promotion Wales. Cardiff, 1999, pp 11-16.
3. Foulds, J. The effects of nicotine and smoking on mood and cognition. In: *Nicotine Addiction In Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians*. Section 3.1, London, 2000, pp 67-72.
4. Foulds, J. Persistent and Compulsive Smoking in the face of Smoking-related ill-health. In: *Nicotine Addiction In Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians*. Section 5.2, London, 2000, pp112-116.
5. Foulds, J. Non-dependent Smokers. In: *Nicotine Addiction In Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians*. Section 5.3, London, 2000 pp116-118.
6. Ziedonis DM, Williams JM, Steinberg ML, Smelson D, Krejci J, Sussner BD, Violette N, Foulds J. Addressing tobacco dependence among Veterans with a psychiatric disorder: a neglected epidemic of major clinical and public health concern. In Isaacs SL (Ed): *VA In The Vanguard: Building on Success In Smoking Cessation*. Department of Veterans Affairs. Pp 141-170. 2005.
7. Foulds J. Risk profile of smokeless tobacco. Pp129-161 In: *Harm Reduction In Nicotine Addiction: Helping People Who Can't Quit*. A report by the Tobacco Advisory Group of the Royal College of Physicians. London: RCP, 2007.
8. Foulds J. Estrategias de reduccion del dano en el tabaquismo. In: Ruiz CJ & Fagerstrom K. (Eds). *Tratado Tabaquismo*. 2007
9. Foulds J, Delnevo C, Zeidonis D, Steinberg M. Health Effects of Tobacco, Nicotine, and Exposure To Tobacco Smoke Pollution. Chapter In, Brick,J (Ed): *Handbook of the Medical Consequences of Alcohol and Drug Abuse* pp423-459. Haworth Press, Binghamton, NY. 2008
10. Oredein T, Foulds J, Edwards NS, Dasika J. Motivating Adolescent Smokers to Quit through a School-Based Program: The Development of Youth Quit2Win. In: Lapointe M (Ed) *Adolescent Smoking and Health Research*. Pp171-190. Nova Science Publishers Inc. New York, 2008.
11. Foulds J, Branstetter S. Tobacco harm reduction. In: Riley D & Pates R (Eds). *Drugs and Harm Reduction*. Wiley-Blackwell. (In Press).

Books:

1. West, R. and Foulds, J. *Smoke-free Schools: Seven Steps To Success*. Health Education Authority. London.1999.

Reports:

1. Bates, C., Foulds, J., Fowler, G. et al. The benefits to public health of increased availability of nicotine replacement therapy: a consensus statement. Imperial Cancer Research Fund. London. 1999.
2. Foulds, J. Services for smokers: recruitment and referral. In: Willis, N. (Ed) Stop: A Guide to Setting Up and Running Services for Smokers. Canterbury, 1999.
3. Foulds, J. Smoking Cessation In Young People: Should we do more to help young smokers to quit? Health Development Agency. London, 2000.
4. Slade J, Zeidonis D, Foulds J, Lindberg D and Order-Connors B (2001). New Jersey Guidelines for Tobacco Dependence Treatment. New Jersey Department of Health and Senior Services.
5. Foulds J, Repetto PD, Zimmermann MH, Dasika J, Burke M, Steinberg M, Order-Connors B, Speelman N, Wackowski O, Richardson D. Youth Quit2Win: Manual for Youth Tobacco Cessation. New Brunswick, NJ. Tobacco Dependence Program at University of Medicine and Dentistry of New Jersey-School of Public Health 2005
6. Aveyard P, Foulds J. The 2008 US Clinical Practice Guideline: the key recommendations and a commentary. www.treatobacco.net 2009 *Ask the Experts*. Accessed 01 March 2009. http://www.treatobacco.net/en/page_349.html
7. Foulds J, Hughes J, Hyland A, Le Houezec J, McNeill A, Melvin C, Okuyemi K, Shiffman S, Wassum K, Williams L, Zeller M. Barriers to Use of FDA-Approved Smoking Cessation medications: Implications for Policy Action. Society for Research on Nicotine and Tobacco. March, 2009. (Paper submitted as evidence base for Citizens' petition to FDA from ATTUD and SRNT). <http://www.attud.org/>

Conference Presentations:

I am regularly invited to speak at national and international meetings and conferences, as well as presenting research data on a competitive submission basis. A selection of examples from recent years is given below:

1. Foulds J. Why it is difficult to give up smoking. WHO International NGO Meeting Against Tobacco. World Health Organisation HQ, Geneva, Switzerland, May 1999 (Invited).
2. Foulds J. The psychology of addiction. European Seminars In Respiratory Medicine, St Moritz, Switzerland, July 1999 (Invited).
3. Foulds J. Smoking cessation in young people: a review of the literature. Health Education Authority Seminar on Smoking Cessation in Young People. London, UK, September, 1999 (Invited).
4. Foulds J. The pros and cons of harm reduction in relation to tobacco. World Health Organisation Meeting on Regulation of Tobacco Products and Tobacco Dependence Treatment Products. Helsinki, Finland, October, 1999 (Invited).

5. Foulds J, Browning S, Johnstone G, Waters A, Stapleton J. Effects of nicotine-yielding versus de-nicotinized cigarettes on mood and performance in abstinent and non-abstinent smokers. Society for Research on Nicotine and Tobacco 2nd European Conference, London UK, November, 1999. (One of 9 out of 80 submissions accepted for oral presentation).
6. Foulds J. New developments in treating tobacco dependence. Annual Conference of the British Diabetic Association, Brighton, (UK). March, 2000 (Invited).
7. Foulds J. When does temporary abstinence create withdrawal? Treating symptoms with NRT. Symposium at World Conference on Tobacco or Health, Chicago (USA), August, 2000 (Invited).
8. Foulds J, Fisher S. Effects of glucose tablets on mood and craving in a smokefree workplace. Symposium at World Conference on Tobacco or Health, Chicago (USA), August, 2000 (Accepted for oral presentation after competitive submission).
9. Foulds J. Treatment for tobacco dependence. Robert Wood Johnson Medical School – “Mini-Medical School” lecture series open to the public. March 2001. (invited)
10. Foulds J. Treating tobacco dependence: what works? Physicians Conference 2001: the annual conference for New Jersey physicians. April, 2001. (invited)
11. Foulds J. Pharmacotherapy for Tobacco Dependence. Philadelphia Health Initiative One Day Training on Tobacco Treatment. March, 2003 (invited).
12. Foulds J. How to run effective group treatment for tobacco dependence. Paper presented at the National Conference on Tobacco or Health, Boston, December, 2003 (accepted after competitive submission).
13. Foulds J. Addressing tobacco in addictions treatment: the New Jersey story. Presentation at CENAR Annual Conference, Worcester, MA. 2004. (Invited) (similar invited workshop presented to New York State, Department of Health, October, 2004, and Washington State Department of Addiction Services, Seattle WA, June 2005)
14. Foulds J. Assessment of Tobacco Dependence. Workshop Presentation, Annual Conference of the American Psychiatric Association, New York NY. 2004. <http://jama.ama-assn.org/cgi/reprint/292/11/1286.pdf>
15. Foulds J. Practical strategies for tobacco dependence treatment. Invited lecture at: 9th annual “Perspectives in Thoracic Oncology” conference, October 1-2, Manhattan NY 2004.
16. Foulds J. A perspective on the role of low nitrosamine smokeless tobacco in reducing smoking caused disease. Invited workshop presentation. Annual Conference of the Society for Research on Nicotine & Tobacco, **Phoenix Arizona**, February 19, 2004. (Invited). Similar invited presentations made to Scottish Home and Health Department, **Edinburgh, UK** (2003) and Canadian Council for Tobacco Control, **Ottawa, Canada** (2004), the California State Tobacco Control Program, **Sacramento, US** (2004).
17. Foulds J. “Tobacco Harm Reduction.” Invited plenary presentation at the First UK National Conference on Smoking Cessation, London, UK. July 9& 10, 2005. The slides and full audio recording of this presentation are available online at: http://www.uknsc.org/2005_UKNSCC/speakers/jonathan_foulds.html

18. Foulds J. Smokeless Tobacco. Invited presentation at a Research Seminar of the European Respiratory Society on "Tobacco Smoking: Harm Reduction Strategies", Ferney-Voltaire, France October 3rd, 2005.
19. Foulds J. "The Science of Nicotine Addiction." and "Challenges In Treating Tobacco Dependence in Addiction and Mental Health Settings.". Invited presentations at the Annual Conference of the Washington State Tobacco Prevention and Control Program. Seattle, Washington. November 2&3, 2005.
20. Foulds J. "Smokeless tobacco: Problems and Opportunities" Invited plenary presentation at the second UK National Conference on Smoking Cessation, Gateshead, UK. June 26, 2006. Audio and slides available online at:
http://www.uknsc.org/2006_UKNSCC/speakers/jonathan_foulds.html
21. Foulds J. "Advantages of 6-session withdrawal-oriented groups as a model for delivering tobacco dependence treatment" Invited debate presentation at the second UK National Conference on Smoking Cessation, Gateshead, UK. June 26, 2006. Audio file available at:
http://www.uknsc.org/2006_UKNSCC/speakers/debate.html
22. Foulds J, Gandhi KK, Steinberg M, Williams JM.. "Are menthol cigarettes more addictive?" Competitive oral presentation at 13th World Conference on Tobacco or Health, Washington DC. July 13th 2006.
23. Foulds J. "Models for tobacco treatment from around the world." Invited oral presentation at 13th World Conference on Tobacco or Health, Washington DC. July 13th 2006.
24. Foulds J. Is snus a model for harm reduction? Might the Swedish experience transfer to other countries? Invited oral presentation at 13th World Conference on Tobacco or Health, Washington DC, July 2006.
25. Foulds J. "Labelling and use indications for approved tobacco dependence treatment medications." Invited oral presentation as part of a one-day pre-conference symposium at the SRNT Annual Conference, on "Increasing access to effective treatments: the case for more flexible regulatory policy." Austin, Texas, February 21st, 2007. Available at:
<http://www.roswelltturc.org/srnt.htm>
26. Foulds J. "The Future of Tobacco Harm Reduction". 92nd Annual Conference of the Tobacco Merchants' Association. Williamsburg, Virginia, May 7, 2007. Available at:
<http://www.tobaccoprogram.org/fouldstma.htm>
27. Foulds J. "Can smokeless tobacco aid smoking cessation: what is the evidence?" Invited plenary presentation at the Society for Research on Nicotine and Tobacco (Europe) Annual Conference. Madrid, Spain. October 4, 2007.
28. Foulds J. "Benefits of allowing smokeless tobacco to compete with smoking". Invited plenary presentation at European Conference on Tobacco or Health. Basle, Switzerland, October 11, 2007.
29. Foulds J. "Are the 5As enough? Tobacco treatment for people with a mental illness." Invited presentation at the National Conference on Tobacco or Health, Minneapolis . October 2007.

30. Foulds J. "Safety and efficacy of NRT: implications for broadening indications and use?" Submitted/accepted presentation at the Society for Research on Nicotine and Tobacco Annual Conference. Portland, Oregon. March 1, 2008.
31. Foulds J. Treating tobacco dependence in people with mental health problems. Invited presentation at National Conference on Tobacco or Health, Phoenix, 2009.
32. Foulds J. New tools for assessing tobacco dependence in a changing economy. Submitted and accepted for presentation at National Conference on Tobacco or Health, Phoenix, 2009.
33. Foulds J. The effect of legislation to increase tobacco taxes on tobacco consumption. Invited presentation at National Conference on Tobacco or Health, Phoenix, 2009.
34. Foulds J. Night smoking: a better measure of tobacco dependence. Invited plenary presentation at the UK National Smoking Cessation Conference, London, 2009. The slides and full audio recording of this presentation are available online at:
http://www.uknsc.org/2009_UKNSCC/speakers/jonathan_foulds.html
35. Foulds J. Lower quit rates among AA and Latino smokers in treatment: mechanisms and generalisability. Invited presentation at: Conference on Menthol Cigarettes. October, 2009. Washington DC
36. Foulds J. Tobacco treatment for High Risk Populations. Invited 2-day training. University of Hawaii, Honolulu, March 11-12, 2010.
37. Foulds J. Invited Keynote address-" Menthol, Night Smoking and Butting Out: Reflections on a Diverse Landscape" & "New Tobacco Products": presentations at Maine Intensive Tobacco Treatment Training & Conference. Bar Harbour, Maine, April 2010.
38. Foulds J. Treating Tobacco Dependence Workshop. Dublin, Ireland May, 2010.
39. Foulds J. Can stopping smoking be bad for mental health? Invited plenary presentation at the UK National Smoking Cessation Conference, Glasgow, Scotland June 2010 . http://www.uknsc.org/2010_UKNSCC/speakers/jonathan_foulds.html
40. Foulds J. Presentation on behalf of SRNT to the Food and Drug Administration at the FDA Scientific Workshop on "Risks and benefits of long term use of nicotine replacement therapy products." Virginia Oct 27, 2010.
<http://www.fda.gov/downloads/Drugs/NewsEvents/UCM232318.pdf>
41. Foulds J. Tobacco dependence treatment: a partial success story of research-based practice. Invited plenary presentation. International Council on Alcohol and Addictions Annual Conference. Cancun, Mexico. November, 2010.
42. Foulds J. New tobacco and nicotine products: evidence about their risks and potential for harm reduction. Invited presentation at: 7th Annual Dartmouth Symposium on Substance Use. Tobacco Harm Reduction: Public Health Paradigm or Oxymoron? Dartmouth College, NH. April, 2011.
<http://www.dartmouth.edu/~dcare/symposium2011/>

Other Activities:

Wrote a regular column on “Freedom From Smoking” for a health website at:
www.healthline.com/blogs/smoking_cessation/ Selected blog posts (from over 200):

What is nicotine withdrawal syndrome? 3/6/07

http://www.healthline.com/blogs/smoking_cessation/2007/03/what-is-nicotine-withdrawal-syndrome.html

Chantix: how does this new stop smoking medicine work? 4/15/07

http://www.healthline.com/blogs/smoking_cessation/2007/04/chantix-how-does-this-new-quit-smoking.html

Can quitting smoking trigger depression? 6/16/07

http://www.healthline.com/blogs/smoking_cessation/2007/06/can-quitting-smoking-trigger-depression.html

Chantix (varenicline) safety. 5/28/08

http://www.healthline.com/blogs/smoking_cessation/2008/05/chantix-varenicline-safety.html

Why have so many New Jerseyans Quit? 6/30/2009

http://www.healthline.com/blogs/smoking_cessation/2009/06/why-have-so-many-new-jersey-smokers.html

Act as “Health Expert” on www.webmd.com smoking cessation community:

<http://exchanges.webmd.com/smoking-cessation-exchange/groupstory/15928905>